Healthcare
•1072 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (1072)
%
| Company | Market Cap | Price |
|---|---|---|
|
Company focuses on oncology programs using Molecular Glue Degraders (MGDs), aligning with Biotech - Oncology.
|
$617.56M |
$10.04
+17.02%
|
|
Zevra Therapeutics is vertically focused on developing and commercializing therapies for rare diseases (NPC, UCDs, VEDS, IH/narcolepsy), directly aligning with Biotech - Rare Diseases.
|
$602.02M |
$11.01
+0.18%
|
|
Prysm iO and related wellness devices fall under medical devices & biometric sensing.
|
$596.91M |
$12.01
-0.33%
|
|
SIGA's TPOXX is a small-molecule antiviral drug, placing the company in Antiviral Small-Molecule Therapeutics.
|
$587.25M |
$8.22
-2.72%
|
|
CMPX develops proprietary bispecific antibodies (e.g., tovecimig, CTX-8371, CTX-10726), the core product category they directly design and advance.
|
$586.32M |
$4.24
+4.18%
|
|
Savara's focus is on rare respiratory diseases (e.g., autoimmune pulmonary alveolar proteinosis) and orphan lung conditions.
|
$582.46M |
$3.37
-1.75%
|
|
The company is focused on neuropsychiatric drug development, specifically psychedelic-based therapeutics for mental health conditions.
|
$581.95M |
$6.22
-4.31%
|
|
Company focuses on proprietary oncology therapeutics using Bicycle molecule platform.
|
$576.19M |
$8.32
-7.25%
|
|
KalVista's EKTERLY (sebetralstat) is an orally delivered small molecule therapeutic approved for acute HAE attacks, directly matching the 'Oral Small Molecule Therapeutics' investable theme.
|
$574.47M |
$11.50
-2.54%
|
|
Lead candidate soquelitinib is an oral small molecule therapeutic, representing Corvus's core product line.
|
$569.88M |
$7.39
+11.30%
|
|
Core ultrasound hardware (Ultrasound-on-Chip) and imaging software constitute Butterfly's primary medical-imaging product line.
|
$563.82M |
$2.28
-10.59%
|
|
MBX directly develops peptide-based therapeutics under its Precision Endocrine Peptide platform, fitting the Peptide Therapeutics category.
|
$557.85M |
$16.69
-0.36%
|
|
Company directly manufactures Surgical Equipment used in operating rooms, including spinal hardware and navigation-assisted devices.
|
$556.37M |
$14.20
+1.50%
|
|
Arvinas' lead programs target cancer (ER degrader vepdegestrant, BCL6 degrader ARV-393, KRAS G12D degrader ARV-806) using PROTACs; core oncology product line.
|
$548.90M |
$7.52
-2.59%
|
|
REGENXBIO's core business revolves around NAV gene therapy platform and its in-house gene therapy product candidates (RGX-121, RGX-202, ABBV-RGX-314), mapping to Biotech - Gene Therapy.
|
$547.75M |
$10.92
-9.83%
|
|
MoonLake's lead asset Sonelokimab is an immunology therapeutic targeting inflammatory diseases (HS, PsA, etc.).
|
$541.24M |
$8.43
+11.95%
|
|
Lexicon's pipeline consists of oral small-molecule therapeutics (pilavapadin LX9211, LX9851, sotagliflozin) and it generates revenue from INPEFA, classifying as an oral small-molecule therapeutics business.
|
$541.14M |
$1.49
-10.24%
|
|
Core business involves monoclonal antibody therapeutics targeting neurodegenerative diseases (e.g., PRX012) and related pipeline assets.
|
$540.96M |
$10.05
-2.80%
|
|
Direct oncology-focused biotech product line via MNPR-101 platform and cancer-targeted radiopharmaceuticals.
|
$537.04M |
$87.82
-14.34%
|
|
Core diagnostic ultrasound equipment is a direct product offering.
|
$536.62M |
$2.17
+15.43%
|
|
Bioventus' Surgical Solutions include ultrasonic bone resection systems (neXus, BoneScalpel) and PNS trial leads, representing direct surgical hardware and devices.
|
$534.76M |
$6.51
-1.66%
|
|
Eton is focused on ultra-rare disease therapies (ALKINDI SPRINKLE, INCRELEX, GALZIN, and pipeline ET-400/ET-600/ET-700/ET-800), aligning with the Biotech - Rare Diseases investable theme.
|
$534.47M |
$19.93
+0.66%
|
|
Directly manufactures dental implants and related prosthetic dental implant devices (premium implant platforms).
|
$527.72M |
$18.91
+0.08%
|
|
Seralutinib is a small-molecule therapeutic drug in development for pulmonary hypertension, representing a core drug modality.
|
$518.25M |
$2.28
-10.59%
|
|
Ocugen's lead programs are ophthalmic gene therapies targeting eye diseases (RP, Stargardt, GA).
|
$516.90M |
$1.79
+1.41%
|
|
Company focuses on oncology therapeutics leveraging protein engineering platforms.
|
$516.07M |
$35.38
-0.76%
|
|
ARCT-032 and ARCT-810 are mRNA-based therapies (gene therapy approach) targeting CF and OTC deficiency.
|
$513.94M |
$18.95
-5.11%
|
|
AirSculpt operates in the medical aesthetics space delivering proprietary contouring procedures, aligning with Medical Devices & Biometrics.
|
$511.97M |
$8.71
+0.11%
|
|
MGPI's Distilling Solutions segment operates as a contract manufacturer for distillates and aging, i.e., contract manufacturing services.
|
$507.12M |
$23.84
-2.65%
|
|
Rigel commercializes oral small-molecule therapeutics, including SYK, IDH1, and RET inhibitors, making this its core product category.
|
$503.65M |
$28.18
-0.77%
|
|
Organogenesis' core wound-care offerings include wound care devices and biomaterial barriers (e.g., PuraPly family) used in wound management.
|
$502.34M |
$3.96
-2.46%
|
|
Esperion directly manufactures and sells oral small-molecule therapeutics (NEXLETOL and NEXLIZET).
|
$501.44M |
$2.53
+2.85%
|
|
Design and manufacture of customized components and subsystems used in medical devices, including X-ray tubes and detectors.
|
$500.49M |
$12.06
+1.09%
|
|
LAB provides SomaScan services to customers (translational/clinical research), i.e., laboratory testing and advisory services.
|
$497.57M |
$1.31
-5.07%
|
|
Avanos markets and sells surgical devices and related equipment (e.g., pain pumps and delivery systems), aligning with the Surgical Equipment category.
|
$494.81M |
$10.70
-4.63%
|
|
Medical Device Components: The CR3 medical headset and related display/optical modules position Kopin as a supplier of medical device components.
|
$486.77M |
$2.99
-8.28%
|
|
Fulcrum's lead asset pociredir is an oral small molecule therapeutic, the core product category the company develops and would commercialize.
|
$485.27M |
$8.99
-7.37%
|
|
Core Lab directly provides Laboratory Testing & Advisory Services for reservoir description and production optimization.
|
$484.30M |
$10.33
-4.35%
|
|
Operates Laboratory Testing & Advisory Services as part of its hospital/clinic network.
|
$484.16M |
$6.55
-0.30%
|
|
Emergent directly develops and commercializes vaccines (BioThrax, ACAM2000) as core Medical Countermeasure products.
|
$483.62M |
$8.91
+0.45%
|
|
Verastem focuses on oncology therapeutics, with AVMAPKI FAKZYNJA CO-PACK as its lead product in cancer.
|
$470.91M |
$8.57
-7.45%
|
|
CTS-related advisory/testing services align with outsourced testing/advisory offerings.
|
$470.80M |
$18.24
-2.25%
|
|
The company markets an Antibody Discovery Platform that enables de novo antibody design and high-throughput validation, aligning with its manufacturing/design capabilities.
|
$469.42M |
$3.68
-8.46%
|
|
Astria's assets (navenibart and STAR-0310) are immunology therapeutics (antibody-based) addressing immune-mediated diseases (HAE and Atopic Dermatitis).
|
$468.97M |
$8.31
-4.04%
|
|
LY T-200 is a first-in-class monoclonal antibody for oncology, a core PureTech asset (Gallop Oncology) in the pipeline.
|
$464.27M |
$18.00
|
|
Cytek's instrument platforms are diagnostic equipment used for cell analysis in research and potential clinical workflows.
|
$462.00M |
$3.67
+1.52%
|
|
Solid is a gene therapy company developing multi-program viral-vector therapies (e.g., SGT-3.00 for DMD, SGT-212 for FA, SGT-501 for CPVT).
|
$461.99M |
$5.96
-7.31%
|
|
Core focus on pediatric orthopedic devices, including implants and braces, which directly aligns with OrthoPediatrics' product portfolio.
|
$452.78M |
$17.93
-1.94%
|
|
Auryon, AlphaVac, AngioVac, and NanoKnife are direct medical devices used in cardiovascular/interventional procedures, aligning with Cardiology Devices.
|
$446.97M |
$11.00
-6.38%
|
|
RPT904 is a monoclonal antibody targeting IgE, classifying as Monoclonal Antibody Therapeutics.
|
$443.00M |
$26.79
-10.52%
|
|
Core product is autologous cell therapy (obe-cel CAR-T) categorized under cell therapy.
|
$441.79M |
$1.66
-6.21%
|
|
Cullinan Therapeutics is a clinical-stage biotech focused on oncology, with assets including bispecific T-cell engagers and a targeted EGFR inhibitor, directly aligning with Biotech - Oncology.
|
$436.71M |
$7.40
+4.23%
|
|
Ceribell's point-of-care EEG device functions as a diagnostic equipment for rapid neurological assessment.
|
$431.91M |
$11.95
-6.64%
|
|
Neurogene is a clinical-stage biotechnology company that directly develops gene therapies (NGN-401) for neurological diseases, i.e., a gene therapy business line.
|
$430.86M |
$30.21
-4.28%
|
|
Lead asset detalimogene voraplasmid is a gene therapy delivered using a non-viral DDX platform, aligning with Biotech - Gene Therapy.
|
$428.77M |
$8.39
-5.20%
|
|
PacBio designs and sells sequencing instruments and related hardware used in genetic analysis, i.e., diagnostic equipment.
|
$426.12M |
$1.42
-8.97%
|
|
Core product category for bunion correction devices and related implants.
|
$418.95M |
$6.66
-0.15%
|
|
FDMT's core business is precision gene therapy developed on its Therapeutic Vector Evolution platform, with lead assets like 4D-150 and 4D-710.
|
$412.29M |
$8.90
-7.29%
|
|
Surmodics' vascular intervention devices (SurVeil DCB, Pounce thrombectomy, Sublime radial access) are direct Cardiology Devices.
|
$409.39M |
$28.63
-0.62%
|
|
VPG provides precision measurement and diagnostic equipment (measurement systems) used for testing and qualification in various industries.
|
$407.66M |
$30.75
-6.39%
|
|
CYH operates hospitals and a broad network of acute care facilities and outpatient sites, i.e., Hospital Services.
|
$406.89M |
$2.90
-7.05%
|
|
ADCT's lead product ZYNLONTA is an antibody-drug conjugate (ADC), a core direct product the company sells.
|
$404.65M |
$4.36
+6.86%
|
|
Oligonucleotide Therapeutics: Korro Bio uses an oligonucleotide-based approach (OPERA) for RNA editing to therapeutically modify RNA.
|
$403.51M |
$42.97
-8.18%
|
|
Evolus sells Evolysse injectable HA dermal fillers, a medical devices/biomaterials product category.
|
$395.88M |
$6.14
-1.92%
|
|
Dental equipment category reflecting 3D printing solutions used for dentures and dental devices (NextDent).
|
$394.23M |
$2.89
-9.69%
|
|
Kamada maintains a biosimilar portfolio in Israel with planned launches, representing a direct revenue stream.
|
$390.86M |
$6.80
-2.72%
|
|
Core oncology-focused therapeutics with DANYELZA (anti-GD2).
|
$389.89M |
$8.61
|
|
Direct product category: bispecific antibody therapeutics developed for immuno-oncology.
|
$388.95M |
$4.77
-1.65%
|
|
iTeos Therapeutics is an oncology-focused biotech developing cancer immunotherapies, including anti-TIGIT antibodies and other immuno-oncology assets.
|
$388.48M |
$10.15
|
|
Mesa's MassARRAY genomics instrumentation and Gyrolab/protein analysis platforms are diagnostic/clinical lab instruments, aligning with Diagnostic Equipment.
|
$385.97M |
$70.75
+3.12%
|
|
Lineage's lead programs OpRegen, OPC1, and ReSonance ANP1 are allogeneic cell therapies, making Biotech - Cell Therapy the core direct product focus.
|
$385.92M |
$1.69
-1.74%
|
|
Defibrillators are cardiology-focused medical devices sold by AHG.
|
$383.46M |
$1.60
-6.98%
|
|
Company's lead assets and platform focus on RNA interference–based therapeutics (ddRNAi), i.e., RNAi Therapeutics.
|
$381.96M |
$14.92
+5.89%
|
|
Lead program iluzanebart is a monoclonal antibody therapeutic targeting TREM2.
|
$375.71M |
$8.05
|
|
VASCEPA/icosapent ethyl is a cardiovascular drug indicated for reduction of major adverse cardiovascular events; core product in Amarin's portfolio.
|
$374.93M |
$18.23
-5.35%
|
|
Core product category; Delcath's hepatic delivery system falls under vascular intervention devices used for targeted liver therapies.
|
$374.21M |
$10.74
-0.78%
|
|
RxSight directly manufactures and sells Ophthalmology Devices (Light Adjustable Lens system and Light Delivery Device) used in premium cataract surgery.
|
$367.97M |
$9.05
-1.15%
|
|
OMI handles medical device consumables used with devices in healthcare settings, aligning with Medical Device Consumables.
|
$365.45M |
$4.77
-1.24%
|
|
Core business: development and commercialization of radiopharmaceuticals for diagnostic imaging and targeted alpha therapies.
|
$360.75M |
$4.86
+15.71%
|
|
NWBO's DCVax platform products are autologous dendritic cell therapies, i.e., a cell therapy business line.
|
$358.65M |
$0.25
+2.66%
|
|
AC Immune develops monoclonal antibodies via SupraAntigen; its pipeline includes antibody-based immunotherapies, fitting Monoclonal Antibody Therapeutics.
|
$354.43M |
$3.55
+0.28%
|
|
Lead candidate ARD-101 is an oral small-molecule therapeutic targeting TAS2R gut receptors to induce satiety, directly aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$352.78M |
$16.26
-1.99%
|
|
Replimune is a cancer-focused biotechnology company developing oncolytic immunotherapies, aligning with Biotech - Oncology.
|
$352.29M |
$4.67
+2.30%
|
|
Rocket’s core platform is viral-vector gene therapies (in vivo AAV and ex vivo LV) delivering genetic material to patients.
|
$351.23M |
$3.27
+0.46%
|
|
Company targets inherited nucleotide repeat expansion diseases (FA, FECD, DM1, HD), a class of rare genetic diseases, which fits the Biotech - Rare Diseases investment theme.
|
$346.86M |
$6.11
-4.08%
|
|
Supply of surgical equipment, including aesthetic laser devices, to a network of clinics.
|
$342.47M |
$3.37
-7.67%
|
|
Medical Imaging tag corresponds to Materialise's Mimics medical imaging software used for planning and analysis.
|
$342.00M |
$5.79
-6.61%
|
|
Tenaya is developing gene therapies (TN-201, TN-401) for cardiovascular genetic diseases using viral vectors, which directly maps to Biotech - Gene Therapy.
|
$341.60M |
$2.10
-5.19%
|
|
QuantaFlo is a diagnostic instrument for peripheral arterial disease (PAD), i.e., diagnostic equipment.
|
$340.79M |
$30.56
-2.55%
|
|
ANX005 (tanruprubart) is a monoclonal antibody therapeutic targeting C1q.
|
$340.11M |
$3.10
-4.91%
|
|
TOI plans to deploy Radiopharmaceutical Therapy (radioligand therapy) as part of its oncology care offering, representing a distinct therapeutic modality and revenue stream.
|
$338.20M |
$3.79
-4.05%
|
|
Core product is a brain-responsive neuromodulation device (RNS System) used for drug-resistant epilepsy.
|
$337.17M |
$10.28
-5.34%
|
|
Home Health Monitoring Devices: Core home-use medical devices (pneumatic compression devices and AffloVest) used for home therapy.
|
$330.59M |
$14.22
-2.40%
|
|
Direct ophthalmic drug development with reproxalap for dry eye and ADX2191 intravitreal therapy for retinal conditions.
|
$330.02M |
$5.51
-4.67%
|
|
Capricor's lead asset, deramiocel, is a cell-based therapy developed from cardiosphere-derived cells aimed at treating DMD cardiomyopathy.
|
$324.07M |
$7.09
-6.96%
|
|
Core product category is wound care devices, a substantial and investable segment.
|
$320.66M |
$37.48
+8.92%
|
|
Lead asset pemvidutide positions Altimmune as a pharmaceutical/biotech developer focused on metabolic and liver disease therapies, a core business area.
|
$317.94M |
$3.92
-2.73%
|
|
Fanapt and bipolar I disorder expansion, plus a broader psychiatry-focused pipeline, align with Neuropsychiatric Drug Development.
|
$312.94M |
$5.31
-3.80%
|
|
MG provides laboratory testing & advisory services as part of asset integrity programs.
|
$312.04M |
$9.96
-2.54%
|
|
Direct focus on developing therapies for rare genetic diseases (OI, AATD-LD) classifies Mereo under Biotech - Rare Diseases.
|
$311.64M |
$1.96
-6.67%
|
Showing page 5 of 11 (1072 total stocks)
Loading industry metrics...
Loading comparison data...
